New SMC advice on treating hepatitis C genotype 3 with Harvoni

harvoni_bottle_and_pill_on_greyOn Monday, the Scottish Medicines Consortium (SMC) updated its advice on the use of the combination direct acting antiviral, ledipasvir/sofosbuvir (Harvoni).

Previously advice has restricted ledipasvir/sofosbuvir for use in genotype 1 and 4; this now extends advice to include use in genotype 3.

Haemophilia Scotland made a patient group submission in support of this change.  Although it is very welcome, it doesn’t change the fact that genotype 3 remains the most difficult genotype to treat with the new therapies.

You can read the advice in full on the SMC website.

Leave a Reply